Introduction
============

*Helicobacter pylori* (*H. pylori*) is a helical, gram-negative micro-aerobic bacterium that colonises the stomach ([@b1-etm-0-0-8654]). It is the major pathogen associated with gastritis, peptic ulcers and gastric cancer ([@b2-etm-0-0-8654]). Certain *H. pylori* genotypes are risk factors for gastric disease, e.g. the vacuolating toxin A-positive and cytotoxin-associated gene A-positive genotypes ([@b5-etm-0-0-8654]). *H. pylori-*positive children present with clinical manifestations that vary widely from *H. pylori*-positive adults, including iron deficiency anaemia ([@b6-etm-0-0-8654]). Furthermore, *H. pylori*-positive children display no adverse digestive system symptoms, except occasional abdominal pain or duodenal ulcers during late childhood. By contrast, *H. pylori*-positive adults are susceptible to various clinically significant diseases, including ulcers and cancer of the gastrointestinal system ([@b7-etm-0-0-8654]). It has been reported that successful eradication of *H. pylori* during childhood increases growth and restores serum acylated ghrelin levels in children ([@b11-etm-0-0-8654]). However, the European and North American Gastroenterology and Nutrition Society does not recommend the detection and treatment of *H. pylori* infection in children due to the low efficacy of the currently recommended *H. pylori* eradication therapy and the lack of broad availability of culture or molecular-based testing ([@b12-etm-0-0-8654]). Therefore, optimised vaccine strategies and a high-performance first-line treatment based on antimicrobial susceptibility profiles are urgently required for the efficient treatment of *H. pylori* infection in children ([@b12-etm-0-0-8654]).

A previous study reported a higher percentage of delayed growth, defined according to the World Health Organization (WHO) age-appropriate criteria (2006 edition) ([@b16-etm-0-0-8654],[@b17-etm-0-0-8654]), in children infected with *H. pylori* compared with controls ([@b18-etm-0-0-8654]), while other studies have reported no effect of *H. pylori* infection on the growth of children ([@b17-etm-0-0-8654]). Thomas *et al* ([@b19-etm-0-0-8654]) reported that the effects of *H. pylori* colonisation on malnutrition and delayed growth during early infancy (age, 5-8 years) did not persist into late childhood. Conversely, Perri *et al* ([@b20-etm-0-0-8654]) and Fialho *et al* ([@b21-etm-0-0-8654]) reported an association between short stature and *H. pylori* infection in older children aged between 8 and 14 years. Furthermore, the effects of *H. pylori* infection on the growth and development of female children have been reported to be associated with puberty ([@b22-etm-0-0-8654]). Tasar *et al* ([@b23-etm-0-0-8654]) reported that *H. pylori* seroprevalence was higher in children with delayed growth compared with the control group. Therefore, the association between the *H. pylori* infection in childhood and delayed growth remains a topic of debate. Routine screening for *H. pylori* in children under 14 years of age is not recommended at present and the Fifth National *H. Pylori* Infection Consensus Report of China only recommended that children with peptic ulcers should undergo examination for *H. pylori* ([@b24-etm-0-0-8654]). As an intragastric infection that begins during infancy ([@b25-etm-0-0-8654]), the effective eradication of *H. pylori* in a paediatric population is critical ([@b13-etm-0-0-8654]). The meta-analysis performed in the present study comprehensively assessed all available published studies to determine the possible association between *H. pylori* infection and delayed growth during childhood.

Materials and methods
=====================

### Literature search

The Meta-analyses of Observational Studies in Epidemiology and Preferred Reporting Items for Systemic Reviews and Meta-Analyses statement guidelines were followed for the literature search in the present study ([@b26-etm-0-0-8654],[@b27-etm-0-0-8654]). PubMed, Exerpta Medica dataBASE, Cochrane Library and the Chinese Biomedical Literature Database were searched for relevant literature using the following terms: '*Helicobacter pylori'* \[medical subject headings (MeSH) terms\] or '*Helicobacter pylori'* or '*H. pylori'*, and 'Growth Disorders*'* (MeSH Terms) or 'disorder, growth*'* or 'growth disorder*'*, 'stunted growth*'* or 'growth, stunted*'* or 'stunting*'*, 'thrive, failure to*'* or 'Failure to Thrive*'* (MeSH Terms), or 'growth retardation*'* or 'growth restriction*'*. Furthermore, the lists of references all the eligible studies were manually reviewed to identify additional studies.

### Inclusion and exclusion criteria

Case-control, cohort and cross-sectional observational studies were included in the present study. All relevant full texts assessing the effect of *H. pylori* infection on delayed growth in children published between January 1st 1994 and January 1st 2019 were included in the present meta-analysis. Case reports, review articles, meta-analyses, duplicate reports, letters to the editor, commentaries, authors\' replies and abstracts presented at conferences were excluded from the present study. Articles with insufficient data were also excluded from the present study after two reviewers performed an independent screening of the abstracts and full texts (SW and YD). Any disagreements were resolved by a third reviewer (LP).

### Quality assessment

To ensure the quality of the meta-analysis, quality assessments of each of the included articles were performed. Quality evaluation of the case-control and cohort studies was performed using the Newcastle-Ottawa Scale ([@b28-etm-0-0-8654]). The methodological quality of the cross-sectional studies was evaluated using the 11-item checklist recommended by the Agency for Healthcare Research and Quality that was applied by a previous meta-analysis ([@b29-etm-0-0-8654]). Higher scores indicated higher quality articles; therefore, articles with a final score of ≥7 points were included in the present study ([@b28-etm-0-0-8654],[@b29-etm-0-0-8654]).

### Data extraction

The basic data were extracted from the studies by two reviewers (SW and YD) and included the following: First author, year of publication, country/continent, sample size, age and gender of participants, prevalence of *H. pylori* infection, study design, *H. pylori* detection method, type of delayed growth, definition of delayed growth and adjustment for confounders. Delayed growth was defined according to the WHO age-appropriate criteria (2006 edition) ([@b16-etm-0-0-8654],[@b17-etm-0-0-8654]). The number of children with delayed growth and healthy participants in the *H. pylori*-positive and *H. pylori*-negative groups was also recorded.

### Statistical analysis

The potential risk of delayed growth in children infected with *H. pylori* was evaluated using a fixed-effects model to estimate the odds ratio (OR) and 95% confidence intervals (CI). Statistical heterogeneity was assessed using the χ^2^ test and I^2^ index. P\<0.10 and I^2^\>50% were considered to indicate statistically significant heterogeneity. I^2^ values of 0-25, 26-50, 50-75 and \>75% were considered to indicate no, low, medium and high heterogeneity, respectively ([@b30-etm-0-0-8654]).

Subgroup analyses were performed based on country/continent, *H. pylori* prevalance, study design, *H. pylori* detection method, type of delayed growth and confounder adjustment. Furthermore, sensitivity analyses were performed to assess whether removing any single study at a later stage affected the primary outcome of the meta-analysis performed in the present study. Begg\'s and Egger\'s linear regression were performed to assess publication bias, as evaluated by funnel plots. Finally, the credibility of the results was estimated using the trim and fill method ([@b31-etm-0-0-8654]). Data analyses were performed using Review Manager (version 5.3; Cochrane) and STATA (version 12.0; StataCorp LP) softwares.

Results
=======

### Baseline characteristics

Of the 488 records initially retrieved, 44 were duplicates and the remaining 444 articles were screened based on titles and abstracts, of which 390 irrelevant studies were excluded. An additional 38 studies were excluded due to insufficient data. Following quality assessment of the remaining 16 observational studies, a total of 15 studies with a quality assessment score of ≥7 ([Tables I-III](#tI-etm-0-0-8654 tII-etm-0-0-8654 tIII-etm-0-0-8654){ref-type="table"}) were included in the present study ([Fig. 1](#f1-etm-0-0-8654){ref-type="fig"}), including two cohort ([@b18-etm-0-0-8654],[@b32-etm-0-0-8654]), eight cross-sectional ([@b20-etm-0-0-8654],[@b21-etm-0-0-8654],[@b33-etm-0-0-8654]) and five case-control ([@b39-etm-0-0-8654]) studies.

The included articles, published between January 1st 1994 and January 1st 2019, comprised 1,371 *H. pylori*-positive and 2,828 *H. pylori*-negative children. Delayed growth was reported in 454 (33.11%) *H. pylori*-positive children and 761 (26.91%) *H. pylori*-negative children. The major characteristics of the included studies are presented in [Table IV](#tIV-etm-0-0-8654){ref-type="table"}.

### Primary outcomes

The prevalence of delayed childhood growth in the *H. pylori*-positive group was significantly increased compared with that in the *H. pylori*-negative group (OR, 1.51; 95% CI, 1.28-1.78; P\<0.00001), with no significant heterogeneity (χ^2^=13.34; I^2^=0%; P^Heterogeneity^*=*0.50; [Fig. 2](#f2-etm-0-0-8654){ref-type="fig"}). The results indicated that there was a positive association between *H. pylori* infection and delayed childhood growth.

### Subgroup analyses

### Country/continent

The 15 observational studies included in the present study consisted of participants from all five continents (Europe, America, Asia, Africa and Oceania). Participants from Europe (OR, 1.61; 95% CI, 1.11-2.35; Z=2.49; P=0.01; I^2^=0%; P^Heterogeneity^=0.80), America (OR, 1.50; 95% CI, 1.16-1.94; Z=3.06; P=0.002; I^2^=2%; P^Heterogeneity^=0.38) and Asia (OR, 1.66; 95% CI, 1.25-2.20; Z=3.49; P=0.0005; I^2^=0%; P^Heterogeneity^=0.59) displayed an association between *H. pylori* infection and delayed childhood growth; however, no association was observed in participants from Africa and Oceania (OR, 0.83; 95% CI, 0.44-1.56; Z=0.58; P=0.56; I^2^=53%; P^Heterogeneity^=0.14; [Fig. 3](#f3-etm-0-0-8654){ref-type="fig"}).

### Prevalence of H. pylori infection

The prevalence of *H. pylori* infection varied among the included studies, ranging from 9.17-81.87% ([Table IV](#tIV-etm-0-0-8654){ref-type="table"}). Delayed growth in children among studies with a *H. pylori* prevalence of ≤30% (OR, 1.71; 95% CI, 1.31-2.23; Z=3.93; P\<0.0001; I^2^=0%; P^Heterogeneity^=0.99) or \>30 but ≤50% (OR, 1.43; 95% CI, 1.10-1.86; Z=2.64; P=0.008; I^2^=34%; P^Heterogeneity^=0.21) was associated with *H. pylori* infection, with no significant heterogeneity (χ^2^=1.38; I^2^=0%; P^Heterogeneity^=0.50). However, there was no association between delayed growth and *H. pylori* infection in studies with a *H. pylori* prevalence prevalence of *\>*50% (OR, 1.36; 95% CI, 0.97-1.90; Z=1.78; P=0.08; [Fig. 4](#f4-etm-0-0-8654){ref-type="fig"}).

### Study design

Of the three types of observational studies included in the present analysis, cross-sectional (OR, 1.43; 95% CI, 1.18-1.73; Z=3.68; P=0.0002) and case-control (OR, 1.81; 95% CI, 1.23-2.67; Z=3.00; P=0.003) studies displayed an association between *H. pylori* infection and delayed childhood growth*.* Cohort studies did not display any association between the two factors (OR, 1.64; 95% CI, 0.89-3.03; Z=1.58; P=0.11). The heterogeneity among the three subgroups was not significant (χ^2^=1.24; I^2^=0%; P^Heterogeneity^=0.54; [Fig. 5](#f5-etm-0-0-8654){ref-type="fig"}).

### H. pylori detection method

In the studies using ^13^C-urea breath tests (UBTs; OR, 1.72; 95% CI, 1.22-2.40; Z=3.14; P=0.002; I^2^=0%; P^Heterogeneity^=0.86) and serum IgG antibodies targeted against *H. pylori* (OR, 1.81; 95% CI, 1.35-2.44; Z=3.97; P\<0.0001; I^2^=0%; P^Heterogeneity^=0.89) detection methods, an association between *H. pylori* infection and delayed childhood growth was detected. However, the studies using other detection methods did not display any association, including the rapid urease test (OR, 1.32; 95% CI, 0.90-1.94; Z=1.43; P=0.15; I^2^=0%; P^Heterogeneity^=0.88), monoclonal faecal antigen enzyme immunoassay testing (OR, 0.55; 95% CI, 0.24-1.25; Z=1.44; P=0.15), PCR amplification of the 23S ribosomal RNA gene (OR, 3.08; 95% CI, 0.98-9.67; Z=1.92; P=0.05) or at least one of three positive examinations \[^13^C-UBT, antibodies to whole-cell *H. pylori* and cytotoxin-associated gene A (CagA) antigens; OR, 1.24; 95% CI, 0.86-1.79; Z=1.17; P=0.24; [Fig. 6](#f6-etm-0-0-8654){ref-type="fig"}\].

### Measures of delayed growth. H. pylori

infection was associated with the incidence of delayed growth when the primary outcome was height (OR, 1.63; 95% CI, 1.32-2.00; Z=4.57; P\<0.00001; I^2^=0%; P^Heterogeneity^=0.72), which suggested that delayed linear growth was associated with *H. pylori* infection. *H. pylori* infection was also associated with delayed growth when height and weight were collectively analysed as the primary outcome (OR, 1.33; 95% CI, 1.00-1.75; Z=1.99; P=0.05; I^2^=33%; P^Heterogeneity^=0.19). No association was observed when the height, weight and mid-upper arm circumference were collectively analysed as the primary outcome (OR, 1.39; 95% CI, 0.52-3.74; Z=0.66; P=0.51) and no heterogeneity was identified among these subgroup analyses (χ^2^=1.34; I^2^=0%; P^Heterogeneity^=0.51; [Fig. 7](#f7-etm-0-0-8654){ref-type="fig"}).

### Confounder adjustment

Subgroup analyses were performed based on confounder adjustment; four studies were adjusted for potential confounders and the pooled OR was 1.32 (95% CI, 1.02-1.70; Z=2.12; P=0.03) with no significant heterogeneity (I^2^=52%; P^Heterogeneity^=0.10). The pooled unadjusted OR value was 1.67 (95% CI, 1.34-2.07; Z=4.63; P\<0.00001) for the remaining 11 studies, with no significant heterogeneity (I^2^=0%; P^Heterogeneity^=0.88). Therefore, the results suggested that *H. pylori* infection was associated with delayed childhood growth, regardless of the adjustment for potential confounders ([Fig. 8](#f8-etm-0-0-8654){ref-type="fig"}).

### Sensitivity analysis

Following the omission of one study at a time, the pooled OR values of the remaining studies ranged from 1.47-1.58 with insignificant heterogeneity (I^2^=0-2%; P^Heterogeneity^\>0.10), and the upper and lower thresholds of the 95% CI were \>1, indicating that none of the results were significantly altered by the removal of one article from the meta-analysis (P^Remainders\'\ effect^\<0.0001; [Table V](#tV-etm-0-0-8654){ref-type="table"}; [Fig. 9](#f9-etm-0-0-8654){ref-type="fig"}).

### Publication bias

The funnel plot analysis suggested that there may be a certain amount of publication bias, since the included studies were not distributed completely symmetrically in the funnel plots ([Fig. 10A](#f10-etm-0-0-8654){ref-type="fig"}). To investigate the potential publication bias, the included studies were evaluated using the Begg\'s and Egger\'s linear regression tests. No significant publication bias was detected using Begg\'s (P\>\|z\|=0.113) or Egger\'s (P\>\|t\|=0.257) linear regression analyses ([Fig. 10B](#f10-etm-0-0-8654){ref-type="fig"}). Furthermore, adjustment of the funnel plots by the trim and fill method did not alter the results and a statistically significant association between *H. pylori* infection and delayed childhood growth was still observed (P\<0.0001), indicating that the results were stable and credible ([Fig. 10C](#f10-etm-0-0-8654){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, the present study was the first to investigate the association between *H. pylori* infection and delayed childhood growth*.* Following searching and screening, low-quality studies ([@b23-etm-0-0-8654]) were excluded and fifteen observational studies involving 4,199 children were used for the meta-analysis performed in the present study. The likelihood of delayed childhood growth was significantly increased in *H. pylori*-positive children compared with that in *H. pylori*-negative children. A series of further analyses indicated that the results of the present study were credible and stable.

Delayed growth is the most significant nutritional problem worldwide, which leads to long-term effects and may occur in utero ([@b44-etm-0-0-8654]). The present study suggested that *H. pylori* infection may be a potential risk factor for delayed childhood growth, particularly linear growth; however, the specific underlying mechanisms require further investigation. It remains elusive whether delayed childhood growth is due to the direct effects of *H. pylori*-induced inflammation or indirect effects of the infection, e.g. anorexia, abdominal pain, malabsorption or diarrhoea. Therefore, delayed growth may be due to direct as well as indirect effects of *H. pylori* infection ([@b45-etm-0-0-8654]). The clinical outcomes of *H. pylori* infection are affected by a number of factors, including virulence, the host gastric mucosa and the environment ([@b46-etm-0-0-8654]).

Clinical symptoms of *H. pylori* infection vary between children and adults, with a lower incidence of gastroduodenal ulcers, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma in children ([@b47-etm-0-0-8654],[@b48-etm-0-0-8654]). *H. pylori*-induced gastric inflammation is less severe in children compared with that in adults, due to the decreased gastric type 17 T-helper cell/interleukin-17 response in children, which is associated with increased activity of the mucosal regulatory T cells ([@b48-etm-0-0-8654]). Therefore, the extra-digestive manifestations of *H. pylori* colonisation in children, including iron deficiency anaemia ([@b6-etm-0-0-8654]), cognitive function ([@b49-etm-0-0-8654]), type I diabetes mellitus ([@b50-etm-0-0-8654]), Henoch-Schonlein purpura ([@b51-etm-0-0-8654]) and delayed growth, require constant medical attention. *H. pylori* infection has been reported in numerous studies as a risk factor for delayed childhood growth ([@b18-etm-0-0-8654],[@b20-etm-0-0-8654],[@b21-etm-0-0-8654],[@b23-etm-0-0-8654],[@b34-etm-0-0-8654],[@b37-etm-0-0-8654],[@b41-etm-0-0-8654]), and of note, Yang *et al* ([@b11-etm-0-0-8654]) reported that eradication of *H. pylori* infection promotes growth in children. A retrospective study indicated that the prevalence of childhood gastric cancer may be reduced by decreasing the prevalence of *H. pylori* infection in adolescents and children ([@b15-etm-0-0-8654]). However, Dehghani *et al* ([@b52-etm-0-0-8654]) suggested that *H. pylori* infection did not affect the calculated standard deviation score (height and body mass index) ([@b52-etm-0-0-8654]). Cherian *et al* ([@b35-etm-0-0-8654]), Janjetic *et al* ([@b38-etm-0-0-8654]), Chiu *et al* ([@b43-etm-0-0-8654]) and Choe *et al* ([@b33-etm-0-0-8654]) reported that childhood growth and puberty are affected by iron deficiency anaemia and *H. pylori* infection, rather than *H. pylori* infection alone. Ortiz-Princz *et al* ([@b46-etm-0-0-8654]) revealed that early identification and intervention of *H. pylori* infection during childhood prevents further serious complications during adulthood, which is consistent with the results of the present study.

In the present meta-analysis, the subgroup analyses demonstrated an association between *H. pylori* infection and childhood growth in European, American and Asian subjects, but not in African and Oceanian subjects. The association was also identified in studies with a *H. pylori* prevalence of ≤50%, but not in studies with a *H. pylori* prevalence of \>50%. A potential explanation for these differences may be different *H. pylori* prevalence, as well as different environmental and nutritional factors in different countries and regions. Other factors associated with the high prevalence of *H. pylori* infection and delayed growth in children are linked to the socio-economic development of the population, which is associated with limited health care resources, insufficient nutrition and a poor living environment, which may have influenced the results obtained ([@b53-etm-0-0-8654]).

Furthermore, only cross-sectional and case-control studies indicated that *H. pylori* infection was associated with delayed growth in children. An improvement in diet and living conditions during the long-term follow-up of cohort studies may impact the outcome. In addition, the ^13^C-UBT and serum IgG antibodies targeted against *H. pylori* detection methods suggested that *H. pylori* infection was associated with delayed growth in children. Although ^13^C-UBT effectively detects *H. pylori* infection ([@b58-etm-0-0-8654]), the detection method has a high rate of false-positives in children aged \<6 years ([@b59-etm-0-0-8654]). A relevant study reported that detection of *H. pylori* using serum IgG antibodies displayed 88.4% sensitivity and 93.4% specificity compared with histology ([@b60-etm-0-0-8654]). Anti-*H. pylori* IgG and IgA antibody titers are higher in children with CagA-positive sera regardless of their age. Therefore, serum IgG or IgA antibodies are recommended for the detection of *H. pylori* in asymptomatic children aged \<6 years ([@b61-etm-0-0-8654]). Non-invasive screening methods may be used for children aged \>6 years based on different situations, while children with adverse gastrointestinal symptoms, including peptic ulcers and dyspepsia, should be evaluated by upper gastrointestinal endoscopy for the diagnosis of associated pathology ([@b62-etm-0-0-8654]). Consistent with the conclusion proposed by Chilengi *et al* ([@b44-etm-0-0-8654]), the subgroup analysis performed in the present study suggested that there was a significant association between *H. pylori* infection and delayed linear childhood growth, regardless of whether or not the potential confounders had been adjusted.

However, the present study had a number of limitations. First, although only medium- and high-quality studies were included, the 15 observational studies were of lower quality than randomized controlled trial which may have affected the objectivity of the major outcomes. Furthermore, delayed childhood growth in the included studies was defined using different guidelines, resulting in different ranges of percentiles or 1-3 standard deviations. These criteria may have overlapped; therefore, they were not distinguished in the subgroup analyses. In addition, the age, growth rate and hormone levels of each group of children may have been different in each study, which may have further impacted the results of the present study. As another possible limitation, environmental factors, inter-individual differences and iron deficiency anaemia may also lead to malnutrition in children; therefore, management of the growth and development of *H. pylori*-positive children should fully consider these comprehensive factors. Finally, omission of relevant published or unpublished studies may have influenced the conclusions made in the present study.

In conclusion, the present study suggested that *H. pylori* infection increased the likelihood of delayed childhood growth, particularly linear growth*.* The results suggested that children with delayed linear growth should be actively assessed and treated for *H. pylori* infection based on their antimicrobial susceptibility profile. Furthermore, it is necessary to establish a uniform standard definition for delayed childhood growth*.* Once diagnosed, the infection should be treated immediately to avoid further profound effects. Future extensive studies of vaccine strategies for the prevention of *H. pylori* infection in children are required. Furthermore, future high-quality and well-designed studies should be performed to further investigate the results obtained in the present study.
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###### 

Quality assessment of cohort studies using the Newcastle-Ottawa quality assessment scale.

                          Selection   Comparability   Outcome                                
  ----------------------- ----------- --------------- --------- ---- ---- ---- ---- ---- --- -----------------------
  Raymond (1994)          \+          \+              \+        no   \+   \+   \+   \+   7   ([@b32-etm-0-0-8654])
  Benavides-Ward (2018)   \+          \+              \+        \+   \+   \+   no   \+   7   ([@b18-etm-0-0-8654])

'+', one score.

###### 

Quality assessment of cross-sectional studies according to the Agency for Healthcare Research and Quality.

  Author (year)     Definition of the source of information   Inclusion and exclusion criteria for exposed and unexposed subjects   Time period used for patient recruitment   Whether or not the subjects are consecutive   Whether evaluators of subjective components of the study are masked to other aspects of the status of the participants   Description of any assessments undertaken for quality assurance purposes (forexample, test/re-test of primary outcome measurements)   Explanation of any patient exclusions from the analysis   Description of how confounding is assessed and/or controlled   Summary of patient response rates and completeness of data collection   Clarification of expected follow-up (if any) and the percentage of patients for which incomplete or follow-up data was obtained   Score   (Refs.)
  ----------------- ----------------------------------------- --------------------------------------------------------------------- ------------------------------------------ --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------- -----------------------
  Perri (1997)      Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      No                                                                                                                                    Yes                                                       Yes                                                            Yes                                                                     No                                                                                                                                8       ([@b20-etm-0-0-8654])
  Choe (2000)       Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      No                                                                                                                                    Yes                                                       Yes                                                            Yes                                                                     No                                                                                                                                8       ([@b33-etm-0-0-8654])
  Lin (2002)        Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      Yes                                                                                                                                   Yes                                                       Yes                                                            Yes                                                                     No                                                                                                                                9       ([@b34-etm-0-0-8654])
  Fialho (2007)     Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      No                                                                                                                                    Yes                                                       Yes                                                            Yes                                                                     No                                                                                                                                8       ([@b21-etm-0-0-8654])
  Cherian (2009)    Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      Yes                                                                                                                                   Yes                                                       No                                                             Yes                                                                     No                                                                                                                                8       ([@b35-etm-0-0-8654])
  Gulcan (2010)     Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      Yes                                                                                                                                   Yes                                                       No                                                             Yes                                                                     No                                                                                                                                8       ([@b36-etm-0-0-8654])
  Mendoza (2014)    Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      Yes                                                                                                                                   Yes                                                       No                                                             Yes                                                                     No                                                                                                                                8       ([@b37-etm-0-0-8654])
  Janjetic (2015)   Yes                                       Yes                                                                   Yes                                        Unclear                                       Yes                                                                                                                      Yes                                                                                                                                   Yes                                                       Yes                                                            Yes                                                                     No                                                                                                                                9       ([@b38-etm-0-0-8654])

###### 

Quality assessment of case-control studies using the Newcastle-Ottawa quality assessment scale.

                       Selection   Comparability   Exposure                                
  -------------------- ----------- --------------- ---------- ---- ---- ---- ---- ---- --- -----------------------
  Oderda (1998)        \+          \+              \+         \+   ++   \+   \+   no   8   ([@b39-etm-0-0-8654])
  Cacciari (1999)      \+          \+              no         \+   ++   \+   \+   no   7   ([@b40-etm-0-0-8654])
  Buyukegebiz (2001)   \+          \+              \+         \+   ++   \+   \+   no   8   ([@b41-etm-0-0-8654])
  Takahashi (2002)     \+          \+              no         \+   ++   \+   \+   no   7   ([@b42-etm-0-0-8654])
  Chiu (2017)          \+          \+              no         \+   ++   \+   \+   no   7   ([@b43-etm-0-0-8654])

'+', 1 score; '++', 2 scores.

###### 

Baseline characteristics of the included studies.

  Author (year)           Country, continent                   Study design      Sample size   Age (years)       Males/female   Detection method                                                                                 Type of delayed growth   (Delayed growth group *H. pylori* +/-)   Control group (*H. pylori* +/-)   *H. pylori* prevalence (%)   Definition of delayed growth                                                                                              Quality score   (Refs.)
  ----------------------- ------------------------------------ ----------------- ------------- ----------------- -------------- ------------------------------------------------------------------------------------------------ ------------------------ ---------------------------------------- --------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------- --------------- -----------------------
  Raymond (1994)          France, Europe                       Cohort            151           0-16              N/A            Rapid urease test                                                                                Height and weight        21/17                                    56/57                             50.99                        Absence of growth hormone deficit                                                                                         7               ([@b32-etm-0-0-8654])
  Perri (1997)            Italy, Europe                        Cross-Sectional   216           3-14              N/A            13C-UBT                                                                                          Height                   8/13                                     41/154                            22.69                        Below the 25th centile value for height                                                                                   8               ([@b20-etm-0-0-8654])
  Oderda (1998)           Italy, Europe                        Case-control      268           5-13              170/98         Serum *H. pylori* IgG antibodies                                                                 Height                   27/107                                   18/116                            16.79                        Below the 3rd centile value of height                                                                                     8               ([@b39-etm-0-0-8654])
  Cacciari (1999)         Italy, Europe                        Case-control      338           2-16              169/169        Serum *H. pylori* IgG antibodies                                                                 Height                   18/138                                   13/169                            9.17                         Stature below the 3rd percentile for the corresponding age                                                                7               ([@b40-etm-0-0-8654])
  Choe (2000)             Korea, Asia                          Cross-sectional   375           10-15             205/170        Serum *H. pylori* IgG antibodies                                                                 Height and weight        18/63                                    45/249                            16.80                        Below the 25th centile values for height or weight                                                                        8               ([@b33-etm-0-0-8654])
  Buyukgebiz (2001)       Turkey, Asia                         Case-control      56            Mean 14.53±1.12   N/A            Serum *H. pylori* IgG antibodies                                                                 Height and weight        16/8                                     12/20                             50.00                        Stature below parental height, retarded bone age (\>2 SD below chronological age) and height velocity \<25th percentile   8               ([@b41-etm-0-0-8654])
  Takahashi (2002)        Japan, Asia                          Case-control      88            1-16              57/31          Serum *H. pylori* IgG antibodies                                                                 Height                   6/35                                     3/44                              10.23                        Height of 1.5-2.0 SD or more below the mean height for age                                                                7               ([@b42-etm-0-0-8654])
  Lin (2002)              China, Asia                          Cross-sectional   356           2-7               206/150        Serum *H. pylori* IgG antibodies                                                                 Height                   34/111                                   30/181                            17.98                        Below the 25th centile value for height                                                                                   9               ([@b34-etm-0-0-8654])
  Fialho (2007)           Brazil, South America                Cross-sectional   353           0.5-14            180/173        13C-UBT                                                                                          Height                   122/75                                   75/81                             55.81                        Below the 25th centile for height                                                                                         8               ([@b21-etm-0-0-8654])
  Cherian (2009)          Sudan, Burundi and Liberia, Africa   Cross-sectional   182           Mean 8.0±4.3      93/89          MFAT MUAC                                                                                        Weight, height and       32/11                                    117/22                            81.87                        Z-score SD below normal (correlating to 5th centile)\<1.64                                                                8               ([@b35-etm-0-0-8654])
  Gulcan (2010)           Turkey, Asia                         Cross-sectional   490           6-15              229/261        Rapid urease test                                                                                Height and weight        51/45                                    180/214                           47.14                        Height and BMI SDS below the 5th percentile                                                                               8               ([@b36-etm-0-0-8654])
  Mendoza (2014)          Mexico, North America                Cross-Sectional   641           6-13              N/A            At least one of three tests with postive results^[a](#tfn1-etm-0-0-8654){ref-type="table-fn"}^   Height                   66/95                                    172/308                           37.13                        Z-score of height for age \<-1 SD                                                                                         8               ([@b37-etm-0-0-8654])
  Janjetic (2015)         Argentina, South America             Cross-Sectional   525           4-16              233/292        ^[13](#tfn1-etm-0-0-8654){ref-type="table-fn"}^C-UBT                                             Height and weight        6/13                                     126/380                           25.14                        Height, weight or BMI-for-age below the 3rd SD                                                                            9               ([@b38-etm-0-0-8654])
  Chiu (2017)             Australia, Oceania                   Case-control      106           4-18              64/42          ^[13](#tfn1-etm-0-0-8654){ref-type="table-fn"}^C-UBT                                             Height and weight        9/17                                     22/58                             29.25                        Height or weight-for-age below the 15th percentile value                                                                  7               ([@b43-etm-0-0-8654])
  Benavides-Ward (2018)   Peru, South America                  Cohort            56            6-12              29/27          PCR amplification of the 23S rRNA gene                                                           Height                   20/13                                    7/14                              48.21                        2.2 SD below the Z-score of height-for-age                                                                                7               ([@b18-etm-0-0-8654])

^a13^C-UBT, antibodies against *H. pylori* whole-cell and CagA antigens. *H. pylori*, *Helicobacter pylori*; UBT, urea breath test; IgG, immunoglobulin G; MFAT, monoclonal faecal antigen enzyme immunoassay testing; MUAC, mid-upper arm circumferences; BMI, body mass index; SDS, standard deviation score; rRNA, ribosomal RNA; CagA, cytotoxin-associated gene A.

###### 

Sensitivity analysis.

  Author (year)           OR (95% CI)        Heterogeneity     Remainders\' effect   (Refs.)
  ----------------------- ------------------ ----------------- --------------------- -----------------------
  Raymond (1994)          1.52 (1.29-1.80)   I^2^=1%; P=0.44   Z=4.89; P\<0.00001    ([@b32-etm-0-0-8654])
  Perri (1997)            1.49 (1.26-1.76)   I^2^=0%; P=0.49   Z=4.69; P\<0.00001    ([@b20-etm-0-0-8654])
  Oderda (1998)           1.50 (1.27-1.78)   I^2^=2%; P=0.43   Z=4.68; P\<0.00001    ([@b39-etm-0-0-8654])
  Cacciari (1999)         1.50 (1.27-1.77)   I^2^=2%; P=0.43   Z=4.71; P\<0.00001    ([@b40-etm-0-0-8654])
  Choe (2000)             1.50 (1.27-1.78)   I^2^=2%; P=0.42   Z=4.68; P\<0.00001    ([@b33-etm-0-0-8654])
  Buyukgebiz (2001)       1.48 (1.25-1.75)   I^2^=0%; P=0.58   Z=4.62; P\<0.00001    ([@b41-etm-0-0-8654])
  Takahashi (2002)        1.50 (1.27-1.77)   I^2^=0%; P=0.46   Z=4.78; P\<0.00001    ([@b42-etm-0-0-8654])
  Lin (2002)              1.48 (1.24-1.76)   I^2^=0%; P=0.47   Z=4.44; P\<0.00001    ([@b34-etm-0-0-8654])
  Fialho (2007)           1.47 (1.23-1.75)   I^2^=0%; P=0.47   Z=4.22; P\<0.0001     ([@b21-etm-0-0-8654])
  Cherian (2009)          1.57 (1.33-1.86)   I^2^=0%; P=0.89   Z=5.28; P\<0.00001    ([@b35-etm-0-0-8654])
  Gulcan (2010)           1.53 (1.29-1.83)   I^2^=0%; P=0.44   Z=4.75; P\<0.00001    ([@b36-etm-0-0-8654])
  Mendoza (2014)          1.58 (1.32-1.90)   I^2^=0%; P=0.44   Z=4.89; P\<0.00001    ([@b37-etm-0-0-8654])
  Janjetic (2015)         1.51 (1.28-1.79)   I^2^=2%; P=0.42   Z=4.85; P\<0.00001    ([@b38-etm-0-0-8654])
  Chiu (2017)             1.51 (1.28-1.79)   I^2^=2%; P=0.42   Z=4.85; P\<0.00001    ([@b43-etm-0-0-8654])
  Benavides-Ward (2018)   1.48 (1.26-1.75)   I2=0%; P=0.54     Z=4.66; P\<0.00001    ([@b18-etm-0-0-8654])

OR, odds ratio.
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